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socially Learned Attitude Change is 
not reduced in Medicated patients 
with schizophrenia
Arndis simonsen  1,2,3,4,5,6, Riccardo Fusaroli3,8, Joshua Charles skewes3, 
Andreas Roepstorff3,4, Ole Mors1,2, Vibeke Bliksted  1,3,4 & Daniel Campbell-Meiklejohn7
Schizophrenia is often associated with distinctive or odd social behaviours. Previous work suggests 
this could be due to a general reduction in conformity; however, this work only assessed the tendency 
to publicly agree with others, which may involve a number of different mechanisms. In this study, we 
specifically investigated whether patients display a reduced tendency to adopt other people’s opinions 
(socially learned attitude change). We administered a computerized conformity task, assumed to rely 
on reinforcement learning circuits, to 32 patients with schizophrenia or schizo-affective disorder and 
39 matched controls. Each participant rated 153 faces for trustworthiness. After each rating, they were 
immediately shown the opinion of a group. After approximately 1 hour, participants were unexpectedly 
asked to rate all the faces again. We compared the degree of attitude change towards group opinion in 
patients and controls. Patients presented equal or more social influence on attitudes than controls. This 
effect may have been medication induced, as increased conformity was seen with higher antipsychotic 
dose. The results suggest that there is not a general decline in conformity in medicated patients with 
schizophrenia and that previous findings of reduced conformity are likely related to mechanisms other 
than reinforcement based social influence on attitudes.
Schizophrenia is often associated with distinctive or odd social behaviours. Already in the 1930s it was suggested 
that this could be due to a decline in responsiveness to social stimuli and studies from the 1960s and 70 s partly 
confirmed this hypothesis, indicating that patients with schizophrenia show reduced conformity to the expressed 
opinions of others1–4. Conformity refers to the act of changing one’s behaviour, opinions or beliefs to match or 
become more similar to those of others5,6.
The studies on conformity in schizophrenia were designed to measure public conformity, i.e. the tendency to 
deliberately and outwardly adopt others’ responses often in spite of clear contradictions to one’s own beliefs and 
without changing one’s belief or attitude7. This has also been referred to as public compliance8,9 and sheds light on 
social behaviour under social pressure.
It is unclear whether reduced conformity in patients with schizophrenia is restricted to public conformity or 
whether they display a general reduction in the tendency to conform to others, including a reduced tendency to 
adopt and maintain others’ behaviours, attitudes and beliefs in the absence of experienced social pressure. This 
has been termed private conformity or private acceptance and results in an internalization of others’ beliefs or 
preferences, i.e. a genuine change in beliefs7,9.
The aim of the current study was to investigate whether attitude change towards group opinion (private con-
formity) is altered in patients with schizophrenia (30/32 medicated) compared to healthy individuals. We used an 
automatic conformity paradigm informed by cognitive neuroscience10,11. In this computerized task, participants 
rate 153 faces for trustworthiness followed immediately by a group rating of the face. Approximately 1 hour later, 
participants are unexpectedly asked to rate all faces again in random order without receiving any information 
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about the group ratings. The advantage of this setup is that there is no immediate social pressure to conform 
and original beliefs as well as change are measured. In addition, the high number of ratings make it unlikely that 
group ratings, seen during the first session, would be consciously remembered in the second session. Therefore, 
conformity in this task likely reflects an immediate, socially learned, change of attitude toward the group opin-
ion12,13 and not simply public conformity. We consider this process to be relatively automatic, since participants 
are specifically asked to give their opinion and there is no task requirement or obvious reason to learn from the 
feedback as they cannot act on the feedback provided during the first round. When they are unexpectedly asked 
to rate the faces again 1 hour later, they presumably cannot deliberately act on the feedback given during the first 
round because they cannot consciously remember it.
Although few imaging studies have directly compared the neural mechanisms underlying public and private 
conformity14, the literature suggests that these are at least partially distinct. For instance, actual changes in opin-
ion (value) or memory result in altered activity in orbitofrontal cortex (OFC)13 or in amygdala/hippocampus14, 
respectively, while public conformity does not result in such changes14,15. On the other hand, executive decisions 
to conform despite privately disagreeing, and thus inhibiting or overriding one’s current beliefs (public con-
formity), are assumed to rely more on prefrontal structures related to executive decision-making16. However, the 
evidence for this is still sparse, presumably due to lack of studies. It is thus entirely possible that patients would 
display impairments in one domain (public conformity) but not the other (private conformity) depending on the 
differential recruitment of brain structures and how these are affected in schizophrenia. For instance, it is well 
known that patients with schizophrenia display impairments in executive function and cognitive inhibition17,18. 
On the other hand, medicated patients display relatively intact learning from negative feedback in non-social 
contexts (e.g. avoidance of monetary loss)19–23 when it involves implicit or automatic learning processes. Such 
learning requires one to associate a low outcome value to a certain action. However, it is less clear whether the 
ability to represent precise expected values is intact in schizophrenia21,24,25.
These latter findings may be particularly relevant for this study, as we are measuring automatic updating of 
opinions (change in value) based on learning about group disagreement. Thus, in case a participant conforms, 
the task requires him/her not only to learn that certain actions are less favourable than expected (others disagree 
with him/her) but also to attribute a relatively precise updated value to the specific face, e.g. this face should be 
rated higher (and not lower) than initially thought. Indeed, imaging studies using this setup suggest that private 
conformity to group opinion is based on similar neural mechanisms as reinforcement learning10,26,27. Specifically, 
disagreement or conflict with group opinion can be seen as negative feedback that triggers deactivation of the 
ventral striatum and activation of the anterior insula (AI) and the dorsal part of the posterior medial frontal 
cortex (pMFC). This signals the discrepancy between preferred (agreement) and actual outcome (disagreement) 
thereby calling for an adjustment of the behaviour, i.e. an attitude change toward group opinion10,26 (when it is 
desirable to be similar to the group28). The final result is an update in OFC of the opinion or value assigned to the 
specific face, in this case13. The pMFC seems crucial in this conformity process27 as the size of the error related 
signal in pMFC predicts subsequent adjustments toward group opinion10,29, while down-regulation of the pMFC 
evoked by repetitive transcranial magnetic stimulation reduces such behavior11.
Interestingly, medicated patients show relatively intact error signals to negative feedback30–32. This 
feedback-related negativity signal (FRN) is also seen when receiving feedback about disagreement in conformity 
tasks, and is thought to correspond to the error-related signal detected in pMFC with fMRI26,33,34. Of course, the 
caveats of reverse inference need to be kept in mind here. For instance, the pMFC has been implicated in a variety 
of cognitive processes such as monetary loss, reduced reward, response conflict, negative feedback, physical and 
social pain, and error detection. It is therefore difficult to pinpoint the exact psychological process; however, it is 
generally assumed that it plays an important role in detecting (negative) changes in the environment that entail a 
subsequent adjustment of behavior9,28. Due to this very reason, the structures most often implicated in conformity 
(VS, AI, pMFC) have been proposed to convey general prediction errors (reinforcement learning)10, cognitive 
inconsistency28 and/or physical arousal and negative affective states15 that guide subsequent conformity. It is 
important to note that these are not mutually exclusive explanations27.
Another issue to keep in mind is that studies within pharmacology35 and genetics36, suggest that dopamine 
plays a role in private conformity to others’ opinion. This is potentially relevant for two reasons. First, schizo-
phrenia is associated with altered dopamine function. Specifically, the acute psychotic state is associated with 
increased dopamine synthesis, release and resting-state dopamine concentrations37. Second, most patients receive 
some type of antipsychotic medication. These consistently block dopamine receptors37. Both of these factors 
could therefore potentially contribute to altered private conformity to others’ opinion in schizophrenia. Although 
it is difficult to predict the net result of these opposing factors, we know from studies on reinforcement learning, 
that both negative feedback learning and the associated FRN may increase with antipsychotic treatment38 and 
that patients’ sensitivity to negative feedback is positively associated with antipsychotic medication dose39,40. To 
the extent that parallels can be drawn between negative feedback learning and conformity to others’ opinions, 
these findings – together with the finding of relatively intact negative feedback learning in medicated patients – 
suggest that antipsychotic medication could play a role in how much one conforms to others’ opinion and that 
medicated patients could display relatively intact conformity. This of course requires that they are able to repre-
sent the updated values of the faces rather precisely. As there are potential medication effects, we also assessed 
whether conformity increased with antipsychotic dose. It should be noted that since we primarily tested med-
icated patients (30/32), we can only detect any potential deficits experienced prior to medication onset insofar 
that these are still present to some extent after medication onset. Finally, we wanted to investigate whether the 
patients’ tendency to conform was associated with their level of functioning, suggesting a possible route to the 
characteristic social impairments in case conformity was reduced.
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Materials and Methods
Participants. The sample included 40 patients with an ICD-10 DCR diagnosis of schizophrenia or schizoaf-
fective disorder and 40 healthy controls. Diagnosis was confirmed using the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN)41,42. Controls were matched pairwise to the patients by age, gender, childhood res-
idence, and (when possible) to commenced educational level and parental socioeconomic status (see Table 1).
Patients were recruited through the Psychiatric Centre of the National Hospital of the Faroe Islands. Controls 
were contacted based on their age and gender and, if they fulfilled the inclusion criteria and matched a patient, 
were offered to participate in the study. All the participants were native speakers of Faroese between the age of 
18 and 55. Exclusion criteria for all participants included: current psychoactive substance use disorders (except 
nicotine), a neurological or medical disorder that could affect brain functioning, severe head trauma and an 
estimated IQ below 70 based on prior history or testing. In addition, the controls were excluded if they took any 
psychotropic medication or if they or a first-degree relative had a history of severe mental disorder. History of 
mental disorder for controls was assessed with SCAN. The participants were screened for recent use of psycho-
active substances (THC/cannabis, opiates, amphetamine, MDMA, benzodiazepines, cocaine) using urine sticks 
(NanoSticka® 200-32). Patients with a positive test were excluded unless they had a prescription for the positive 
drug (e.g. benzodiazepines). None of the controls had a positive test.
Two patients had to be excluded as they did not fulfil inclusion criteria. Seven participants (6 patients, 1 
control) only performed the first round of the task due to various reasons: one control and one patient only gave 
extremely high/low ratings, respectively, resulting in unbalanced feedback (i.e. they did not receive the full range 
of feedback possible in the task and higher/lower feedback only occurred on less than 4% of the trials instead 
of approximately 1/3 - see below for detailed task description), one patient said they did not understand task 
instructions, one did not want to perform the task, and one produced no variation in the ratings (>99% of ratings 
were identical). Two patients did not have time to perform the second round of the task. Thirty-two patients and 
thirty-nine controls performed both rounds of the task.
Medication. At the time of testing, twenty-five patients had been on a stable dose of antipsychotic medication 
for at least 3 weeks, while five had adjustments made. Two patients were not taking antipsychotic medication.
Although antipsychotics may target several receptors and neurotransmitter systems, modulation of the D2 
receptor seems to be a necessary and sufficient condition to obtain antipsychotic effects43. Antipsychotic med-
ication doses can be converted into a common scale (e.g. chlorpromazine equivalents) based on their clinical 
efficacy. Importantly this efficacy is closely and specifically related to the occupancy of the dopamine D2 receptor 
(60–80%) and not, for instance, the serotonin 5-HT2A receptor or other dopamine receptors44–46. Drugs with a 
high dissociation constant like clozapine and quetiapine also reach similar levels of occupancy, although it drops 
faster than with typical antipsychotics44,47. We converted all antipsychotic doses to chlorpromazine (CPZ) equiv-
alents48,49 (see Table 2 for details). Some patients also took other types of medication (see Table S1).
General procedure. The conformity task was administered as part of a larger battery of cognitive tasks. 
Symptom severity and level of functioning were assessed with the Scale for the Assessment of Positive/Negative 
Symptoms (SAPS/SANS)50,51 and the Personal and Social Performance Scale (PSP)52, respectively (see Table 1). 
The work complied with the ethical standards of the relevant national committees. The study was approved by 
the national ethics committee of the Faroe Islands, Vísindasiðsemisnevndin, and reported to the data protec-
tion agency, Dátueftirlitið. The work was carried out in accordance with the Declaration of Helsinki and written 
informed consent was obtained from all participants after the procedure had been explained.
Schizophrenia 
(n = 32)
Controls 
(n = 39)
Age, mean (SD) 38.0 (11.1) 39.2 (10.6)
No. of males:females 21:11 27:12
Educational level commenceda, mean (SD) 2.0 (0.7) 2.3 (0.7)
Years of education, mean (SD) 12.1 (2.6) 14.2 (3.1)
No. of high: middle parental SESb 12:20 13:26
Level of functioning (PSP), mean (SD) 59.0 (15.4) 85.8 (4.9)
Positive symptoms (SAPS)c, mean (SD) 4.6 (4.2) —
Negative symptoms (SANS)d, mean (SD) 7.4 (4.5) —
CPZ equivalent dose in mg, mean (SD) 686 (561) —
Table 1. Demographic and Clinical Characteristics of Patients and Controls. aEducational level commenced 
divided into 4 levels: 1: primary school (up to 10 years of education), 2: secondary school/technical training, 3: 
bachelor program, 4: master program. bParental socioeconomic status (SES) was divided into 3 levels: where a 
high SES corresponds to one of the parents having a high education + at least a middle annual income (above 
200.000 DKK) or a middle education + a high income (above 400.000 DDK), while a middle SES corresponds to 
a high education + low income (below 200.000 DDK), a middle education + middle income (200.000–400.000 
DDK) or no education + at least a middle income. None of the parents had a low SES. cSAPS score is the total 
score of the 4 items: global rating of severity of hallucinations, delusions, bizarre behavior and the global rating 
of positive formal thought disorder. dSANS score is the total score of the 5 items: global rating of affective 
flattening, alogia, avolition-apathy, anhedonia-asociality and attention.
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The conformity task. The conformity task was based on the task used in Klucharev et al.10 and was adapted 
from Campbell-Meiklejohn et al.35 and Simonsen et al.53. It consists of two rounds. On each trial of the first round, 
the participant rates a face for trustworthiness on an 8-point scale ranging from not at all trustworthy (1) to very 
trustworthy (8). Immediately after each rating, feedback of how other people rated the face (group opinion) is 
shown, as well as the difference between participant’s and the others’ rating (−3, −2, 0, 2, 3 points) (see Fig. 1). 
153 randomized pictures of female faces were rated in total. After approximately 60 min. of solving other tasks, 
participants were asked to rate the faces again in a new random order. Participants were unaware that they had 
to rerate the faces until instructed to do so. No feedback on others’ ratings was given during the second round.
In order to provide an adequate number of trials in each condition, and minimize the number of participants 
required in the study, others’ ratings were generated pseudo-randomly by the computer with the following cri-
teria: in approximately 1/3 of the trials, these ratings agreed with the participant’s rating, in approximately 1/3 
ratings were two or three points lower than the participant’s, and in approximately 1/3 ratings were two or three 
points higher. The participants were told that the others’ ratings that matched their own rating within ±1 point 
would be shown as agreement (difference score of 0). The task was presented on a 19 in. computer screen using 
Presentation v. 16.3 (Neurobehavioral Systems).
Statistical analysis. All analyses were set up as mixed effects (also called multilevel or hierarchical) regres-
sion models with changes in rating (second rating – first rating) as outcome, and feedback (−3, −2, 0, 2, 3), initial 
rating (1 to 8) and group (schizophrenia, controls) as fixed effects. Initial ratings were included to take any effects 
due to regression to the mean into account54. Variance inflation factors (VIF) were assessed in order to evaluate 
any issues with collinearity between initial rating and feedback. VIF provides an index of how much the variance 
of a coefficient is increased because of collinearity, with values of above 10 or even 4 often considered indicators 
of a potential problem55. Additionally, we ran an analysis including only ratings with well-matched feedback (i.e. 
only including initial ratings of 4 or 5, or initial ratings of 3 or 6 when feedback was −2, 0, or 2), to assess the 
robustness of the results. Finally, since both including initial ratings in the analysis or only analysing a subset of 
the data may provide conservative estimates of degree of conformity we reran the analysis on the whole dataset 
without including initial rating to assess a potential group difference in conformity.
There was not a pairwise match between all participants, however, data from the 32 patients and 39 controls 
were included in the analysis as the statistical methods employed are robust to moderate imbalance in the groups 
and, while preserving pairwise matching when present, they can rely on the additional data to reduce uncertainty 
in the estimates56. To account for the pairwise matching of participants, when present, matched individuals were 
assigned a common identifier, and entered as random intercept. As the one-to-one matching cannot be assumed 
to be homogeneous across all pairs, we included a random slope for group. This procedure explicitly estimates the 
non-independence introduced by matching and adjusts standard errors accordingly, which is a more conserva-
tive procedure than just assuming homogeneous matches. Analogously, we included random slopes for feedback 
and initial rating. Picture stimuli were also entered as random intercepts, and random slopes were included for 
feedback, initial rating and group.
When assessing the association between antipsychotic medication or level of functioning and conformity, the 
main analysis was run in patients only and the variable in question as well as potential confounders (e.g. symptom 
Antipsychotic medication
mg per day/
injection
no. of 
patientsd
Oral
Amisulpridec 116.3 1
Aripiprazoleb 4 7
Chlorprothixenec 83.3 2
Clozapinec 66.7 6
Olanzapineb 3 9
Quetiapineb 60 5
Zuclopenthixolc 8.3 3
Depota
Paliperidoneb 15 2
Perphenazine decanoatec 41.4 1
Risperidoneb 10 3
Zuclopenthixol decanoatec 66.4 4
Table 2. Chlorpromazine (CPZ) 100 mg/day dose equivalency. aDepot antipsychotics were first converted to 
oral equivalencies of the same drug using suggested equivalencies based on studies of oral to depot switch77 
or manufacturer’s recommendation78,79 and then converted to CPZ equivalents (see note b and c). For 
perphenazine decanoate we used the average minimum effective dose of perphenazine decanoate80 and equated 
it with the lowest recommended target dose of oral perphenazine49 and then converted to CPZ equivalents (see 
note c). bFor the second-generation antipsychotics, we used Leucht et al.48 to convert to CPZ equivalents when 
possible except for clozapine where the conversion result was highly questionable. cFor other antipsychotics 
(including clozapine), we used Gardner et al.49 to convert to CPZ equivalents. dEighteen patients were taking 
one antipsychotic, 11 were taking two and one was taking three.
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severity) were added as fixed effects, but otherwise maintaining the random structure of the full model. In order 
to investigate the robustness of a potential medication effect, we adjusted for a range of potential confounders: 
symptom severity, level of functioning, other medications or excluding patients with recent medication changes. 
In addition, we assessed whether we would see similar effects in patients receiving different types of antipsy-
chotics. For instance, aripiprazole has a slightly different profile than the other antipsychotics. It is a functionally 
selective D2 ligand with both antagonistic and agonistic properties depending on the signalling environment of 
the D2 receptor57. We therefore looked at conformity effects within patients receiving aripiprazole vs. other antip-
sychotics. Similarly, we assessed whether effects were similar in patients receiving clozapine/quetiapine (high 
dissociation constant) vs. other antipsychotics (lower dissociation constant).
If a model could not converge, we simplified the random structure removing one random slope at a time until 
model estimation converged58. In case of null results on theoretically relevant questions, a follow up analysis 
was performed to assess the evidence in favour of the null hypothesis by estimating a Bayes factor (BF), which 
compares the relative likelihood of the null and of the alternative hypotheses given the observed data. If one 
hypothesis is more likely than the other given the data, there is evidence for that hypothesis over the other. The 
relative likelihood corresponds to relative evidence given the observed data, and is expressed as Bayes Factor. To 
calculate Bayes Factors we followed the procedure in Rouder and Morey (2012) for linear models with mixed 
effects (BayesFactor 0.9.12-2.) which employs Liang uninformative priors59,60, that is, a lack of prior expectations 
as to which hypothesis is better supported by the data. Bayes Factors below 1/3 were interpreted as substantial 
evidence in favour of the null hypothesis (more than 3 times as much evidence for the null hypothesis compared 
to the alternative hypothesis). Bayes Factors above three were interpreted as substantial evidence in favour of the 
alternative hypothesis (more than 3 times as much evidence for the alternative hypothesis compared to the null 
hypothesis). Values below 1 and approaching 1/3 favour the null over the alternative and vice versa, while values 
close to 1 do not present enough evidence to favour any of the hypotheses61,62.
All analyses were run using R 3.563 and lme4 1.1-1764. Residuals were assessed with DHARMa65. Influential 
data points were checked with leave-one-out diagnostics66. To calculate p-values of the individual factors we 
treated the t-statistic as if it were a z-statistic (i.e., using a normal approximation), the most conservative estima-
tion in large datasets58. The variance explained by the model was calculated using marginal R2 (R2m, including 
fixed factors only) and conditional R2 (R2c, full model including random structures), using MuMIn 1.40-467. For 
model specifications and parameter estimates of the main analyses, see Tables S2 to S14 in the Supplementary 
Information.
Figure 1. The conformity task, modified from Campbell-Meiklejohn et al.35. Participants rated 153 faces, one 
by one, for trustworthiness on a scale from 1 to 8. The choice was highlighted by a green vertical rectangle. After 
rating a face, participants learned the group opinion of that face, highlighted by a horizontal blue rectangle so 
that overlap with the participant’s response could be observed. Unexpectedly, participants rated the faces again 
after 1 hour, in a random order, without social feedback. Display was presented to participants in colour.
www.nature.com/scientificreports/
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Results
Ratings and feedback. In order to make sure that the task worked as expected in both groups, we assessed 
the mean and standard deviation of the ratings during the first and second round, as well as the number of times 
each type of feedback (lower, same, higher) was shown, see Table 3 for details. As can be seen from the table, the 
patients gave slightly lower and more variable ratings during both rounds compared to controls. The group dif-
ference was significant for average initial ratings (β = −0.31, SE = 0.14, t = −2.28, p = 0.03) but not for the second 
rating or the standard deviations (ps > 0.09). However, despite this group difference, both groups received a sim-
ilar number of ratings for each type of feedback, and importantly also for feedback that was lower than the initial 
rating (ps > 0.5). The feedback was not perfectly balanced though: both groups received around 5-6 agreement 
trials more than anticipated, on average, and correspondingly fewer trials where group feedback was higher than 
the initial rating. However, since the feedback was so similar in the two groups, the computer-generated feedback 
was largely successful and this slight imbalance is unlikely to have affected the results.
Socially learned attitude change in schizophrenia. As expected, there was a main effect of feedback 
(β = 0.018, SE = 0.008, t = 2.202, p = 0.03) and initial ratings (β = −0.663, SE = 0.021, t = −31.874, p < 0.001) 
on change of trustworthiness ratings. We did not observe a significant interaction between feedback and group 
(β = 0.008, SE = 0.013, t = 0.573, p = 0.567, R2m = 0.374, R2c = 0.496) (see Fig. 2) and the BF indicated substantial 
evidence of no difference in change to feedback in the two groups (BF = 0.023).
There was a correlation between initial rating and feedback due to the task design. However, the correlation 
was not very high (r = −0.396, SE = 0.009) when considering concerns of collinearity68. Consistent with this the 
variance inflation factors (VIFs) indicated no problem with the model (VIFs < 1.4). When running the analysis 
without initial rating on a subset of the data where initial ratings were matched across the different feedback 
conditions, the results were indeed highly similar to the above (main effect of feedback across groups: β = 0.030, 
SE = 0.009, t = 3.241, p = 0.001; interaction between feedback and group: β = −0.001, SE = 0.019, t = −0.052, 
p = 0.958, BF < 0.001). This latter approach effectively ensures no correlation between initial rating and feedback 
(r = 0.001, SE = 0.012), as well as avoids the confounder of regression to the mean with feedback, albeit it reduces 
the dataset from 153 to 99 data points per participant, on average.
Interestingly, when we adopted a less conservative procedure (i.e., analysing the whole dataset and not 
adjusting for initial ratings), patients did display significantly more conformity compared to controls (β = 0.053, 
SE = 0.016, t = 3.226, p = 0.001, R2m = 0.06, R2c = 0.08).
Antipsychotic medication, level of functioning and attitude change. We observed an inter-
action between feedback and medication on change (for every 100 mg increase in CPZ: β = 0.006, SE = 0.002, 
t = 2.435, p = 0.021, R2m = 0.37, R2c = 0.491, see Fig. 3). This indicates that the higher the dose, the more the 
patient conformed to feedback. The interaction remained significant when adjusting for other types of medication 
(antidepressants, anticholinergics, proton-pump-inhibitors, hormonal contraceptives, benzodiazepines, corticos-
teroids, NSAID) (β = 0.011, SE = 0.003, t = 4.046, p < 0.001, R2m = 0.371, R2c = 0.487), negative symptom sever-
ity (β = 0.006, SE = 0.003, t = 2.266, p = 0.03, R2m = 0.371, R2c = 0.491), positive symptom severity (β = 0.008, 
SE = 0.003, t = 2.976, p = 0.005, R2m = 0.37, R2c = 0.488), level of functioning (β = 0.008, SE = 0.003, t = 3.068, 
p = 0.004, R2m = 0.37, R2c = 0.49), or when excluding the 5 patients with recent medication changes (β = 0.006, 
SE = 0.003, t = 2.323, p = 0.028, R2m = 0.364, R2c = 0.482). In these models there was not a significant interaction 
between feedback and negative symptom severity (β > −0.001, SE = 0.003, t = −0.036, p = 0.971, BF = 0.034) or 
positive symptom severity (β = −0.005, SE = 0.003, t = −1.599, p = 0.121, BF = 0.19) on change. PSP showed a 
statistical trend indicating higher conformity in patients with a higher level of functioning when adjusting for 
medication dose (β = 0.002, SE = 0.001, t = 1.772, p = 0.086).
Patients receiving aripiprazole (7 patients) and patients receiving other antipsychotics (23 patients) showed 
a similar interaction between feedback and dose on change (aripiprazole: β = 0.011, SE = 0.004, t = 2.506, 
p = 0.032, R2m = 0.323, R2c = 0.397; other antipsychotics: β = 0.006, SE = 0.003, t = 1.815, p = 0.083, R2m = 0.363, 
R2c = 0.482) and the BF indicated substantial evidence of no difference between these groups (BF = 0.054). It 
should be noted that 5 out of 7 patients receiving aripiprazole also received other types of antipsychotic medica-
tion. Similarly, patients receiving clozapine/quetiapine (11 patients) and patients receiving other antipsychotics 
(19 patients) showed a similar interaction between feedback and dose on change (clozapine/quetiapine: β = 0.012, 
SE = 0.004, t = 2.952, p = 0.003, R2m = 0.381, R2c = 0.489; other antipsychotics: β = 0.008, SE = 0.004, t = 2.244, 
p = 0.036, R2m = 0.34, R2c = 0.443) and the BF indicated substantial evidence of no difference between these 
groups (BF = 0.046). Four out of 11 patients receiving clozapine/quetiapine also received other types of antipsy-
chotic medication.
Schizophrenia 
(n = 32)
Controls 
(n = 39)
Initial rating, mean (SD) 4.7 (1.9) 5.0 (1.6)
Second rating, mean (SD) 4.8 (1.8) 5.0 (1.6)
No. of ratings with group giving lower feedback, mean (SD) 49.7 (2.62) 50.7 (0.88)
No. of ratings with agreement feedback, mean (SD) 56.6 (4.70) 55.8 (5.77)
No. of ratings with group giving higher feedback, mean (SD) 46.7 (5.21) 46.4 (5.91)
Table 3. Ratings and Feedback.
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Discussion
We found that medicated patients with schizophrenia do not present a reduced tendency to conform to others’ 
opinions when there is minimal social pressure. In fact, patients displayed at least similar or even enhanced levels 
of attitude change towards group opinion compared to healthy individuals. The results suggest that patients with 
schizophrenia – at least when medicated – cannot be characterized as suffering from a general decline in con-
formity behaviour as previous literature would suggest1–4. Reduced conformity may be restricted to situations that 
require deliberate considerations as to whether to conform to social pressure or not (public conformity). Such 
situations may rely heavily on situational scripts and considerations about how to tactfully deal with situations 
in which there is conflict between being honest and being agreeable69. As such, they are assumed to rely more on 
Figure 2. The effect of feedback on change in trustworthiness ratings in the two groups. Individual dots 
correspond to estimates for individual participants and were calculated as the participant-level random slope 
of feedback in a statistical model predicting change from feedback, group and initial ratings. The horizontal 
line is the mean for each group, the coloured bars indicate 95% Bayesian Credible Intervals of the mean and the 
background violin shapes, the distribution of the data.
Figure 3. Relationship between antipsychotic medication dose and change to feedback as estimated for each 
individual patient. The shadow represents 95% confidence interval.
www.nature.com/scientificreports/
8Scientific RepoRts |           (2019) 9:992  | https://doi.org/10.1038/s41598-018-37250-x
prefrontal structures related to executive decision-making16. Consistent with this idea, patients display impair-
ments in executive function and cognitive inhibition17,18.
Our finding is consistent with studies reporting intact negative feedback learning in reinforcement learning 
tasks19–23. This study places these important effects in a social context where updates to beliefs and behaviour 
happen rapidly within a single trial (as opposed to reinforcement learning over multiple trials). Indeed, the mech-
anism behind private conformity to others’ opinions has been proposed to rely on reinforcement learning circuits 
where disagreement or conflict with group opinion is seen as negative feedback that triggers a prediction error 
signal in the ventral striatum and pMFC10,26, resulting in an update in opinion, represented in OFC13.
It could be argued that a potentially enhanced tendency to conform to others’ opinions actually reflects a 
deficit. There are several factors that suggest that this was not the case. First, conformity was not associated with 
symptom severity. Second, there was a trend association between higher level of functioning and increased con-
formity. This is in the opposite direction to what would be expected, if increased conformity reflected a deficit 
and suggests that increased susceptibility to social influence is beneficial. Third, the degree of attitude change in 
patients was dose-dependent: the higher the antipsychotic dose, the more change towards group opinion was 
seen. This suggests that increased susceptibility to social influence may be medication induced. If this is indeed 
the case, then the treatment may mask a potential trait deficit in conformity or resolve a potential state deficit, 
and in theory, antipsychotic medication could render patients more susceptible to social influence compared to 
healthy individuals, as we see when not controlling for regression to the mean.
The association between medication dose and conformity remained significant when controlling for other 
medications, symptom severity and level of functioning and was similar in patients receiving different antipsy-
chotics. The observed association is consistent with recent studies on schizophrenia showing increased sensitivity 
to negative feedback in non-social contexts with increasing antipsychotic medication dose39,40 and a normaliza-
tion of response to negative feedback when on medication38. Similar medication effects are also seen in Tourette’s 
syndrome70. As conformity and negative feedback learning can be modulated pharmacologically in healthy indi-
viduals35,53,71, we expect the effect seen in this study to not be specific to schizophrenia but a general effect of 
modulating the neurotransmitter systems.
The mechanism behind this possible antipsychotic medication effect is not known; however, previous lit-
erature suggests that the enhanced conformity might be mediated by enhanced error signalling in pMFC to 
disagreement10,11,27 and antipsychotic treatment seems to enhance these error signals38. Frank et al.71,72 have put 
forward a neurocomputational model on how this may come about. Specifically, learning from positive and neg-
ative feedback is suggested to depend on differences in functioning of two distinct pathways in the basal ganglia 
(BG), where specifically negative feedback learning would rely on transient cessation of tonic dopamine cell firing 
(dopamine dips) causing release of inhibition of the indirect pathway and reduced activity in the direct pathway 
thereby suppressing inappropriate or unrewarding responses71,72. These prediction error signals originating in the 
BG are thought to reach the pMFC that acts as a control filter recruiting necessary adjustments when required 
and to modulate the pMFC activity thus resulting in larger error signals to unfavourable outcomes73. Importantly, 
the model predicts how dopamine modulation affects learning, e.g. D2 blockade with chronic antipsychotic 
administration should have a similar effect on the indirect pathway as dopamine dips resulting in increased 
learning from negative feedback71,72. The indirect pathway with its D2 receptors is thought to play a critical role in 
modulating the activity in pMFC resulting in a larger FRN or a stronger hemodynamic signal when an outcome 
is worse than expected73. Of course, it is not sufficient to increase the error signals in pMFC if patients have dif-
ficulties representing precise values (of e.g. faces) in OFC. However, our results suggest that patients are indeed 
able to represent the updated value attributed to the individual faces rather precisely, as they would not be able to 
conform otherwise, i.e. they would not know whether a rating “should be” higher or lower than initially assumed. 
Whether Frank et al.’s model extends to private conformity to others’ opinions would have to be formally tested. 
Alternatively, enhanced conformity may be mediated by antipsychotic medication induced alterations in oxytocin 
functioning74. Previous studies in healthy individuals suggest that oxytocin may enhance conformity75,76.
The study has some limitations. First, as most of the patients in this study were medicated, it is not clear 
whether unmedicated patients would display reduced conformity compared to controls. Future studies in 
drug-naïve patients could shed further light on this. Second, as patients were not randomized to different treat-
ments, we cannot exclude that unmeasured individual differences accompanying medication dose contributed to 
the observed association between medication dose and conformity.
In summary, medicated patients with schizophrenia do not display a reduction in social influence on attitudes 
on a task shown to evoke conflict-driven attitude change within established reinforcement-learning systems. 
Social deficits and previous findings of residual non-conformity in schizophrenia are likely related to mechanisms 
other than reinforcement based social influence on attitudes. Intact susceptibility to social influence may be a 
result of antipsychotic treatment. Future studies can build on this finding to investigate further the mechanisms 
by which treatment may modulate social learning and explore other cognitive mechanisms of non-conformity 
in schizophrenia.
Data Availability
The dataset analysed during the current study is available from the corresponding author on reasonable request.
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